Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Healthcare | Drug Manufacturers - Major | Switzerland
financial highlights | statements
Index- P/E15.33 EPS (ttm)5.68 Insider Own9.30% Shs Outstand2.52B Perf Week4.75%
Market Cap219.88B Forward P/E15.81 EPS next Y5.51 Insider Trans0.26% Shs Float2.50B Perf Month1.92%
Income13.33B PEG2.34 EPS next Q1.28 Inst Own11.30% Short Float0.08% Perf Quarter5.56%
Sales52.67B P/S4.17 EPS this Y15.20% Inst Trans0.06% Short Ratio1.09 Perf Half Y13.13%
Book/sh33.67 P/B2.59 EPS next Y6.19% ROA9.70% Target Price98.50 Perf Year1.59%
Cash/sh5.83 P/C14.95 EPS next 5Y6.55% ROE17.90% 52W Range72.30 - 94.19 Perf YTD3.74%
Dividend2.98 P/FCF62.25 EPS past 5Y-3.50% ROI7.10% 52W High-7.97% Beta0.82
Dividend %3.42% Quick Ratio1.00 Sales past 5Y-0.70% Gross Margin67.40% 52W Low19.89% ATR1.18
Employees125000 Current Ratio1.20 Sales Q/Q3.40% Oper. Margin28.00% RSI (14)57.76 Volatility1.15% 1.09%
OptionableYes Debt/Eq0.41 EPS Q/Q-21.30% Profit Margin25.40% Rel Volume2.65 Prev Close87.10
ShortableYes LT Debt/Eq0.29 EarningsOct 18 BMO Payout47.20% Avg Volume1.85M Price86.68
Recom1.00 SMA201.35% SMA502.71% SMA2006.14% Volume2,081,913 Change-0.48%
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-22-18 03:38PM  Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates Zacks
10:32AM  BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store? Zacks
08:08AM  This tiny biotech spun a quick $2 billion from $12 million MarketWatch
Oct-21-18 08:49AM  Better Buy: Biogen Inc. vs. Amgen Inc. Motley Fool
Oct-20-18 10:30AM  Novartis drug cut death risk by 35 pct in gene mutation breast cancer Reuters
Oct-19-18 08:28AM  The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Pfizer and Novartis ACCESSWIRE
Oct-18-18 07:46PM  [$$] Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion The Wall Street Journal
02:58PM  Endocyte's $2.1 Billion Deal Rewards Investors Who Stuck It Out Bloomberg
01:30PM  Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion GuruFocus.com
01:04PM  FDA snubs Novartis bid to repurpose inflammation drug for heart attacks Reuters
11:06AM  Novartis buying cancer drug maker Endocyte for $2.1B Yahoo Finance Video
10:29AM  Novartis Reports Positive Long-Term Data From Cosentyx Trials Zacks
09:41AM  Novartis Gets Key Therapy -- For Almost 200 Times Its Last Price Bloomberg
09:35AM  Why Endocyte, Inc. Stock Is Soaring Today Motley Fool
09:16AM  Novartis Secures Prostate Cancer Treatment With Endocyte Deal TheStreet.com
09:06AM  Novartis To Buy Endocyte In $2.1B Deal Benzinga
08:20AM  [$$] Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion The Wall Street Journal
07:56AM  The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs Benzinga
07:24AM  Endocyte stock pops 50% on $2.1 bln Novartis acquisition MarketWatch
06:24AM  [$$] European Equities Market Talk Roundup The Wall Street Journal
05:31AM  Novartis pushes deeper into nuclear medicine with $2.1 billion deal Reuters
05:19AM  Novartis: 3Q Earnings Snapshot Associated Press
05:00AM  Novartis pushes deeper into nuclear medicine with $2.1 bln deal Reuters
04:36AM  [$$] European Corporate News Roundup The Wall Street Journal
03:39AM  Endocyte Enters Into Agreement to be Acquired by Novartis for $24/Share Benzinga
02:58AM  Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash Reuters
02:33AM  Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash Reuters
02:28AM  Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash Reuters
01:50AM  Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate Reuters
01:29AM  Novartis to buy Endocyte for $2.1 billion in cash Reuters
01:08AM  Novartis CEO: No fundamental changes to operations from B... CNBC Videos
Oct-17-18 02:31PM  Novartis Q3 Earnings Preview Benzinga
Oct-16-18 01:02PM  Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG TheStreet.com
10:26AM  Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization Benzinga
09:49AM  Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark TheStreet.com
09:39AM  Roche Announces Positive Data on Breast Cancer Drug Kadcyla Zacks
08:28AM  Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU Reuters
08:00AM  Tilray's stock surges after Benchmark starts coverage with bullish rating, $200 target MarketWatch
Oct-15-18 06:04PM  Trump administration: Drug makers should disclose prices in TV ads Yahoo Finance
Oct-12-18 03:29PM  AbbVie Permits US Sale of Sandoz's Humira Biosimilar GuruFocus.com
10:25AM  Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks
09:23AM  AbbVie Settles With Novartis to Delay Humira Biosimilar in US Zacks
08:14AM  Abbvie settles Humira patent disputes with Novartis unit Reuters
Oct-11-18 09:30PM  Abbvie settles Humira patent disputes with Novartis unit Reuters
06:04PM  Abbvie settles Humira patent disputes with Novartis unit Reuters
04:56PM  AbbVie stock ticks higher as Humira patent dispute with Novartis resolved MarketWatch
09:28AM  Novartis Presents Data on Multiple Sclerosis Drug Gilenya Zacks
Oct-10-18 05:23PM  Novartis Presents Positive Data on Sickle Cell Disease Drug Zacks
07:56AM  The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares Benzinga
Oct-09-18 04:53PM  Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study PR Newswire
09:29AM  In a small San Francisco office, Big Pharma zeroes in on digital health American City Business Journals
Oct-08-18 09:40AM  Novartis' Applications for MS Drug Accepted by FDA & EMA Zacks
Oct-05-18 09:57AM  Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data Zacks
Oct-04-18 03:20AM  Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US Moody's
Oct-03-18 07:19PM  [$$] Boston Pharma Adds to War Chest in Pacts With Novartis, GlaxoSmithKline The Wall Street Journal
11:28AM  Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies Zacks
10:23AM  Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs Zacks
07:54AM  The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares Benzinga
Oct-01-18 11:53AM  Rare manufacturing glitch raises concern over CAR-T therapies: study Reuters
11:08AM  Rare manufacturing glitch raises concern over CAR-T therapies -study Reuters
11:00AM  Rare manufacturing glitch raises concern over CAR-T therapies -study Reuters
Sep-28-18 11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
10:07AM  Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs Zacks
08:00AM  Report: Developing Opportunities within AstraZeneca, Manulife Financial, Infosys, Novartis AG, Black Hills, and Shell Midstream Partners Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-27-18 02:41PM  [$$] Cellular Biomedicine, Novartis in CAR-T Cell Therapy Pact The Wall Street Journal
01:34PM  Novartis strikes deal with Chinese firm to make Kymriah Reuters
08:36AM  [$$] Stock of China's GenScript Plummets on Report Critical of Unit's Gene-Therapy Tests The Wall Street Journal
Sep-26-18 03:20PM  Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs Zacks
Sep-25-18 11:31PM  [$$] Novartis to Cut 2,000 Jobs Amid Revamp The Wall Street Journal
04:59PM  Novartis Layoffs 2018: NVS to Cut 2,000 + Jobs InvestorPlace
01:18PM  Match Group on an upswing, Starbucks up, Novartis on the rise Yahoo Finance
01:03PM  Match Group, Starbucks and Novartis are the Yahoo Finance charts of the day. Yahoo Finance Video
11:33AM  Ann Taylor's parent company reports major beat, Google CEO heads to Washington, Boeing pulls major upset Yahoo Finance
11:06AM  Ann Taylor's parent company reports major beat, Google CEO heads to Washington, Boeing pulls major upset Yahoo Finance Video
07:16AM  [$$] Novartis to Cut 2,000 Jobs Amid Revamp The Wall Street Journal
06:18AM  Novartis plans to cut 2,100 jobs in Switzerland, Britain Associated Press
06:06AM  Novartis to cut 2,550 jobs in Switzerland, UK in profit push Reuters
05:35AM  [$$] European Corporate Roundup The Wall Street Journal
04:07AM  [$$] Novartis Cuts Over 2,000 Jobs in Switzerland The Wall Street Journal
04:00AM  What Investors Should Know About Novartis AGs (VTX:NOVN) Financial Strength Simply Wall St.
03:56AM  [$$] Novartis slashes jobs in UK and Switzerland Financial Times
02:48AM  Novartis to cut 2,200 jobs in Switzerland to boost profitability Reuters
Sep-24-18 04:00PM  Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar Zacks
Sep-21-18 08:03PM  [$$] We Cant Afford the Drugs That Could Cure Cancer The Wall Street Journal
09:30AM  Should Value Investors Pick Novartis AG (NVS) Stock? Zacks
09:30AM  NVS vs. AZN: Which Stock Is the Better Value Option? Zacks
08:50AM  [$$] Triple Set of EMA Recommendations for Novartis Drugs The Wall Street Journal
07:32AM  Spark's Luxturna blindness therapy gets European panel nod Reuters
Sep-20-18 02:07PM  Novartis Is Ready to Rally From a Large Base Pattern TheStreet.com
11:00AM  Eli Lilly Prices Animal Health Unit IPO at $24 Per Share Zacks
08:49AM  Cannabis Company Tilray's (TLRY) Shares Up 856% Since July Zacks
Sep-19-18 03:43PM  Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation Benzinga
02:59PM  [$$] Novartis' CAR-T Drug Hits First Setback in Europe The Wall Street Journal
07:45AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
05:56AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
05:05AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
04:59AM  Novartis Cancer Therapy Kymriah Hits First Hurdle in Europe Bloomberg
Sep-17-18 01:19PM  Novartis links bonuses to ethics in bid to rebuild reputation Reuters
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerAug 20Sale2.3020,38846,8922,396,882Aug 22 04:34 PM
Novartis Bioventures Ltd10% OwnerAug 20Sale3.905,30020,6705,800,250Aug 22 04:07 PM
Novartis Bioventures Ltd10% OwnerAug 17Sale2.108,70018,2702,417,270Aug 20 05:12 PM
Novartis Bioventures Ltd10% OwnerAug 16Sale2.108,80818,4972,425,970Aug 20 05:12 PM
Novartis Bioventures Ltd10% OwnerAug 15Sale2.152,6355,6652,434,778Aug 16 04:18 PM
Novartis Bioventures Ltd10% OwnerAug 14Sale2.263,3007,4582,437,413Aug 16 04:18 PM
Novartis Bioventures Ltd10% OwnerAug 13Sale2.361,6003,7762,440,713Aug 14 05:05 PM
Novartis Bioventures Ltd10% OwnerAug 10Sale2.445,61513,7012,442,313Aug 14 05:05 PM
Novartis Bioventures Ltd10% OwnerAug 09Sale2.482355832,447,928Aug 10 04:29 PM
Novartis Bioventures Ltd10% OwnerAug 08Sale2.781,0002,7802,448,163Aug 10 04:29 PM
Novartis Bioventures Ltd10% OwnerAug 07Sale2.971,7395,1652,449,163Aug 08 04:21 PM
Novartis Bioventures Ltd10% OwnerAug 06Sale3.022,9428,8852,450,902Aug 08 04:21 PM
Novartis Bioventures Ltd10% OwnerAug 02Sale3.334,70215,6582,453,844Aug 06 04:22 PM
Novartis Bioventures Ltd10% OwnerAug 01Sale3.228,18126,3432,458,546Aug 02 04:33 PM
Novartis Bioventures Ltd10% OwnerJul 31Sale3.074,50013,8152,466,727Aug 02 04:33 PM
Novartis Bioventures Ltd10% OwnerJul 30Sale3.272,0006,5402,471,227Jul 31 04:16 PM
Novartis Bioventures Ltd10% OwnerJul 27Sale3.386,45821,8282,473,227Jul 31 04:16 PM
Novartis Bioventures Ltd10% OwnerJul 26Sale3.637,93728,8112,479,685Jul 27 04:21 PM
Novartis Bioventures Ltd10% OwnerJul 25Sale3.8412,46047,8462,487,622Jul 27 04:21 PM
Novartis Bioventures Ltd10% OwnerJul 24Sale4.117002,8772,500,082Jul 25 04:35 PM
Novartis Bioventures Ltd10% OwnerJul 23Sale4.2530,600130,0502,500,782Jul 25 04:35 PM
Novartis Bioventures Ltd10% OwnerJul 17Sale4.7112,50058,8752,531,382Jul 18 04:17 PM
Novartis Bioventures Ltd10% OwnerJul 16Sale5.153001,5452,543,882Jul 18 04:17 PM
Novartis Institutes for BioMed10% OwnerApr 23Buy15.00766,66611,499,9903,948,482Apr 23 04:43 PM
open in yahoo | open in reuters | open in google